Although chemerin appears to be a promising biomarker for numerous inflammation-related lung diseases, standardizing measurement techniques is crucial to obtain reproducible results across different centers and facilitate its implementation in routine clinical practice. This evidence concerns the gene RARRES2 and lung disorder.